GlassScriptPhysician profile
Amanda D Barton
NPI 1528452067
$3,314.92
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,315 · 2022: $767 · 2023: $1,108 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.97 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $599.55 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $530.51 | 2021-2024 | |
| Astellas Pharma US INC | $238.72 | 2021-2023 | Veozah, Myrbetriq |
| Lilly USA, LLC | $229.53 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.95 | 2021-2023 | Jardiance, Synjardy |
| Pfizer INC. | $136.50 | 2021-2024 | |
| Kerecis Limited | $131.69 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Otsuka America Pharmaceutical, INC. | $124.34 | 2022-2023 | Rexulti |
| Organogenesis INC. | $112.08 | 2023 | Puraply Antimicrobial |
| Amarin Pharma, INC. | $102.64 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $93.50 | 2021-2023 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $89.91 | 2021 | |
| Esperion Therapeutics, INC. | $88.10 | 2021 | |
| Lundbeck LLC | $79.97 | 2022-2024 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.15 | 2021-2023 | Xifaxan, Trulance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $48.27 | 2021-2023 | Regranex, Collagenase Santyl |
| Abbott Laboratories | $47.18 | 2021-2022 | |
| Hologic Sales and Service, LLC | $40.13 | 2024 | Aptima |
| Amgen INC. | $36.44 | 2023 | Otezla, Repatha |
| Nevro Corp. | $32.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $30.86 | 2022-2023 | Quviviq |
| Shield Therapeutics INC | $30.68 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $26.56 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $24.35 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.96 | 2021 | |
| Irhythm Technologies, INC. | $23.77 | 2023 | Zio Xt Patch |
| Allergan, INC. | $23.61 | 2021 | |
| Glaxosmithkline, LLC. | $21.36 | 2021 | |
| Eisai INC. | $21.22 | 2021 | |
| Amneal Pharmaceuticals LLC | $19.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.94 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $17.59 | 2021 | |
| Axsome Therapeutics, INC. | $16.27 | 2023 | Auvelity |
| Phadia US INC. | $13.17 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.